Changes in the Neuronal Architecture of the Hippocampus in a 6-Hydroxydopamine-Lesioned Rat Model of Parkinson Disease

키워드

참고문헌 (35)

1. Collaborators G, "GBD 2016 Dementia Collaborators Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016", Lancet Neurol, 2019, pp.88~106 (2019)
2. Van Den Eeden SK, "Incidence of Parkinson’s disease: variation by age, gender, and race", ethnicity, 2003, pp.157, 1015~1022
3. Changjong Moon, "Therapeutic Approaches to Non-Motor Symptoms of Parkinson's Disease: A Current Update on Preclinical Evidence", Current Neuropharmacology, 21(3), pp.560~577 (2022), Bentham Science Publishers Ltd.[DOI]
4. Maetzler W, "Parkinson disease in 2017 : changing views after 200 years of Parkinson disease", Nat Rev Neurol, 14, pp.70~72 (2018)
5. Yeojin Bang, "Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson’s disease: clues to early diagnosis and effective treatment", Archives of Pharmacal Research, 44(6), pp.588~604 (2021), 대한약학회[DOI]
6. Barone P, "Quality of life and nonmotor symptoms in Parkinson’s disease", Int Rev Neurobiol, 133, pp.499~516 (2017)
7. Brandao PRP, "Cognitive impairment in Parkinson’s disease : a clinical and pathophysiological overview", J Neurol Sci, 419, pp.117177~ (2020)
8. Weerasinghe-Mudiyanselage PDE, "Structural plasticity of the hippocampus in neurodegenerative diseases", Int J Mol Sci, 23, pp.3349~ (2022)
9. Bliss TV, "Long-term potentiation in the hippocampus : discovery, mechanisms and function", Neuroforum, 24, pp.A103~A120 (2018)
10. Calabresi P, "New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson’s disease", Lancet Neurol, 12, pp.811~821 (2013)
11. Esmaeili-Mahani S, "Apelin-13 prevents hippocampal synaptic plasticity impairment in Parkinsonism rats", J Chem Neuroanat, 111, pp.101884~ (2021)
12. Costa C, "Mechanisms underlying the impairment of hippocampal longterm potentiation and memory in experimental Parkinson’s disease", Brain, 135, pp.1884~1899 (2012)
13. Schaefers AT, "Developmental neuroplasticity and the origin of neurodegenerative diseases", World J Biol Psychiatry, 17, pp.587~599 (2016)
14. Keller TA, "Structural and functional neuroplasticity in human learning of spatial routes", Neuroimage, 125, pp.256~266 (2016)
15. Hotulainen P, "Actin in dendritic spines : connecting dynamics to function", J Cell Biol, 189, pp.619~629 (2010)
16. Verkhratsky A, "Astroglia in neurological diseases", Future Neurol, 8, pp.149~158 (2013)
17. Wang Y, "Transcranial magneto-acoustic stimulation improves neuroplasticity in hippocampus of Parkinson’s disease model mice", Neurotherapeutics, 16, pp.1210~1224 (2019)
18. Weerasinghe-Mudiyanselage PDE, "Acute MPTP treatment impairs dendritic spine density in the mouse hippocampus", Brain Sci, 11, pp.833~ (2021)
19. Sepulveda B, "Short-and longterm effects of LRRK2 on axon and dendrite growth", PLoS One, 8, pp.e61986~ (2013)
20. Winner B, "Adult neurogenesis and neurite outgrowth are impaired in LRRK2G2019S mice", Neurobiol Dis, 41, pp.706~716 (2011)
21. Schultz W, "Depletion of dopamine in the striatum as an experimental model of parkinsonism : direct effects and adaptive mechanisms", Prog Neurobiol, 18, pp.121~166 (1982)
22. Ang MJ, "Melatonin alters neuronal architecture and increases cysteine-rich protein 1 signaling in the male mouse hippocampus", J Neurosci Res, 98, pp.2333~2348 (2020)
23. 강소희, "Chronic Treatment with Combined Chemotherapeutic Agents Affects Hippocampal Micromorphometry and Function in Mice, Independently of Neuroinflammation", Experimental Neurobiology, 27(5), pp.419~436 (2018), 한국뇌신경과학회
24. Guatteo E, "Pathophysiological features of nigral dopaminergic neurons in animal models of Parkinson’s disease", Int J Mol Sci, 23, pp.4508~ (2022)
25. Grealish S, "Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson’s disease", Eur J Neurosci, 31, pp.2266~2278 (2010)
26. Su RJ, "Timecourse behavioral features are correlated with Parkinson’s diseaseassociated pathology in a 6-hydroxydopamine hemiparkinsonian rat model", Mol Med Rep, 17, pp.3356~3363 (2018)
27. Antunes MS, "Hesperidin ameliorates anxiety-depressivelike behavior in 6-OHDA model of Parkinson’s disease by regulating striatal cytokine and neurotrophic factors levels and dopaminergic innervation loss in the striatum of mice", Mol Neurobiol, 57, pp.3027~3041 (2020)
28. Borgkvist A, "Dopamine in the hippocampus is cleared by the norepinephrine transporter", Int J Neuropsychopharmacol, 15, pp.531~540 (2012)
29. Koyama Y, "Alterations in dendrite and spine morphology of cortical pyramidal neurons in DISC1-binding zinc finger protein(DBZ)knockout mice", Front Neuroanat, 9, pp.52~ (2015)
30. Yoon DH, "Regulation of dopamine D2 receptor-mediated extracellular signal-regulated kinase signaling and spine formation by GABAA receptors in hippocampal neurons", Neurosci Lett, 586, pp.24~30 (2015)
31. Janakiraman U, "Influences of Chronic Mild Stress Exposure on Motor, Nonmotor Impairments and Neurochemical Variables in Specific Brain Areas of MPTP", Probenecid Induced Neurotoxicity in Mice, 2016, pp.11, e0146671~
32. Meredith GE, "Effects of dopamine depletion on the morphology of medium spiny neurons in the shell and core of the rat nucleus accumbens", J Neurosci, 15, pp.3808~3820 (1995)
33. Sy HN, "MPTP-induced dopaminergic degeneration and deficits in object recognition in rats are accompanied by neuroinflammation in the hippocampus", Pharmacol Biochem Behav, 95, pp.158~165 (2010)
34. Thameem Dheen S, "Microglial activation and its implications in the brain diseases", Curr Med Chem, 14, pp.1189~1197 (2007)
35. Cheung YT, "Cytokines as mediators of chemotherapy-associated cognitive changes : current evidence, limitations and directions for future research", Plos One, 8, pp.e81234~ (2013)

관련 논문AI추천